Country
Full text data for US and EP
Status
Type
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC
No.
Publication Number
Title
Publication/Patent Number Publication/Patent Number
Publication date Publication date
Application number Application number
Filing date Filing date
Inventor Inventor
Assignee Assignee
IPC IPC
1
US9150874B2
Publication/Patent Number: US9150874B2
Publication date: 2015-10-06
Application number: 13/834,813
Filing date: 2013-03-15
Abstract: Isolated nucleic acid fragments and recombinant constructs comprising such fragments encoding delta-9 elongases along with a method of making long-chain polyunsaturated fatty acids (PUFAs) using these delta-9 elongases in plants.
2
US9150880B2
Publication/Patent Number: US9150880B2
Publication date: 2015-10-06
Application number: 12/567,334
Filing date: 2009-09-25
Abstract: Novel compositions for the production of the light and heavy chains of an antibody are provided. These novel compositions are also used to produce germline transgenic birds that can successfully pass the transgene encoding the antibody to their offspring. The compositions comprise components of vectors, such as a vector backbone, a promoter, and a gene of interest that encodes the light or heavy chain of an antibody, and the vectors comprising these components. In certain embodiments, these vectors are transposon-based vectors. Also provided are methods of making these compositions and methods of using these compositions for the production of the light and heavy chains of an antibody. In one embodiment, the antibody is a human monoclonal antibody. Novel compositions for the production of the light and heavy chains of an antibody are provided. These novel compositions are also used to produce germline transgenic birds that can successfully pass the transgene encoding the antibody to their offspring. The compositions ...more ...less
3
US9150889B2
Publication/Patent Number: US9150889B2
Publication date: 2015-10-06
Application number: 13/522,288
Filing date: 2011-01-15
Abstract: The disclosure provides a process that converts CO2 to higher alcohols (e.g. isobutanol) using electricity as the energy source. This process stores electricity (e.g. from solar energy, nuclear energy, and the like) in liquid fuels that can be used as high octane number gasoline substitutes. Instead of deriving reducing power from photosynthesis, this process derives reducing power from electrically generated mediators, either H2 or formate. H2 can be derived from electrolysis of water. Formate can be generated by electrochemical reduction of CO2. After delivering the reducing power in the cell, formate becomes CO2 and recycles back. Therefore, the biological CO2 fixation process can occur in the dark. The disclosure provides a process that converts CO2 to higher alcohols (e.g. isobutanol) using electricity as the energy source. This process stores electricity (e.g. from solar energy, nuclear energy, and the like) in liquid fuels that can be used as high octane number gasoline ...more ...less
4
US9150902B2
Publication/Patent Number: US9150902B2
Publication date: 2015-10-06
Application number: 11/994,126
Filing date: 2006-06-28
Abstract: A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof. A novel modified polysaccharide, a solid phase to which the polysaccharide is adhered, methods for detecting N-deacetylase activity, N-sulfotransferase activity and N-deacetylase/N-sulfotransferase activity in a sample which utilizes said solid phase, and detection kits thereof. ...more ...less
5
US9150903B2
Publication/Patent Number: US9150903B2
Publication date: 2015-10-06
Application number: 12/597,311
Filing date: 2008-04-25
Inventor: Reed, Guy L.  
Abstract: Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a plasmin substrate, thereby increasing plasmin activity in the patient. Also provided are methods for the identification of compounds or molecules that increase plasmin activity, comprising determining whether the compound or molecule binds to a binding site on α2-antiplasmin which increases the conversion of α2-antiplasmin from an inhibitor to a plasmin substrate, wherein the compound or molecule is not an antibody, thereby identifying a compound or molecule which increases plasmin activity. Further provided are pharmaceutical compositions and methods of use thereof for the treatment of myocardial infarction, thrombosis, ischemic stroke, and pulmonary embolism. Methods for increasing plasmin activity in a patient in need thereof are provided, comprising administering to the patient a therapeutic amount of an agent which binds to α2-antiplasmin at a binding site to increase conversion of cc2-antiplasmin from an inhibitor to a ...more ...less
6
US9150905B2
Publication/Patent Number: US9150905B2
Publication date: 2015-10-06
Application number: 14/381,967
Filing date: 2013-05-08
Abstract: Compositions and methods are described for standardizing the DNA amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of DNA templates that contains rearranged lymphoid cell DNA encoding T cell receptors (TCR) or immunoglobulins (IG). The presently disclosed embodiments are useful to overcome undesirable bias in the utilization of a subset of amplification primers, which leads to imprecision in multiplexed high throughput sequencing of amplification products to quantify unique TCR or Ig encoding genomes in a sample. Provided is a composition comprising a diverse plurality of template oligonucleotides in substantially equimolar amounts, for use as a calibration standard for amplification primer sets. Also provided are methods for identifying and correcting biased primer efficiency during amplification. Compositions and methods are described for standardizing the DNA amplification efficiencies of a highly heterogeneous set of oligonucleotide primers as may typically be used to amplify a heterogeneous set of DNA templates that contains rearranged lymphoid cell DNA encoding T ...more ...less
7
US9150912B2
Publication/Patent Number: US9150912B2
Publication date: 2015-10-06
Application number: 14/115,785
Filing date: 2012-05-04
Assignee: QIAGEN GMBH
Abstract: The present application discloses a labeled nucleotide comprising a label attached via a linker, wherein said labeled nucleotide has the formula wherein R1 is a residue with a negative net charge, preferably selected from the group consisting of a phosphate group, and a sulphate group; wherein R2, R3 and R4 are independently selected from the group consisting of H2, OH2, and O; wherein “n” is an integer between 0 and 16; wherein “a” is an integer between 1 and 10; wherein SP is absent or a spacer; wherein X is said label; and wherein Y is a nucleotide or nucleoside. Furthermore, oligonucleotides comprising a labeled nucleotide according to the present invention and the use as a primer in amplification based methods is disclosed herein. The present application discloses a labeled nucleotide comprising a label attached via a linker, wherein said labeled nucleotide has the formula wherein R1 is a residue with a negative net charge, preferably selected from the group consisting of a phosphate group, and a sulphate ...more ...less
8
US9150545B2
Publication/Patent Number: US9150545B2
Publication date: 2015-10-06
Application number: 14/390,381
Filing date: 2013-03-14
Abstract: The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. The carboxamide compounds are compounds of the general formula (I) in which R1, R2 and n have the meanings mentioned in the claims and the description, Y is a radical of the formulae (Y1) or (Y2) where # indicates the point of attachment of Y to the pyridine ring, R3, R4, R5, Ry and m have the meanings mentioned in the claims and the description, A is (CH2)p with p being 1, 2, 3 or 4, where one or two hydrogen atoms may be replaced by a radical R6, where A is attached to the 3- or 4-position of the pyrazole radical and R6 has the meaning mentioned in the claims and the description; A1 is (CH2)q with q being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C1-C4-alkyl; and A2 is (CH2)r with r being 0, 1, 2 or 3, where one or two hydrogen atoms may be replaced by halogen or C1-C4-alkyl, provided that that r+q is 2, 3, 4, 5 or 6; their tautomers, the hydrates thereof, the pharmaceutically suitable salts of the carbox-amide compounds (I), the prodrugs of (I) and the pharmaceutically suitable salts of the prodrugs, tautomers or hydrates of (I). The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide ...more ...less
9
US9150552B2
Publication/Patent Number: US9150552B2
Publication date: 2015-10-06
Application number: 14/470,836
Filing date: 2014-08-27
Abstract: The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith. ...more ...less
10
US9150555B2
Publication/Patent Number: US9150555B2
Publication date: 2015-10-06
Application number: 13/879,475
Filing date: 2011-10-13
Abstract: The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt. The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide ...more ...less
11
US9150556B2
Publication/Patent Number: US9150556B2
Publication date: 2015-10-06
Application number: 12/596,152
Filing date: 2008-05-15
Abstract: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.
12
US9150348B2
Publication/Patent Number: US9150348B2
Publication date: 2015-10-06
Application number: 14/370,339
Filing date: 2013-01-02
Assignee: TYPE22 B.V.
Abstract: An air cargo container comprising a skeleton structure of interconnected frame members to which are arranged face panels forming at least one wall between the frame members. At least one of the walls comprises an opening providing access to the interior of the container, whereby the opening covers substantially the complete surface area of said wall between the outermost of the frame members. Parts of the outermost frame members forming the peripheral edge of the opening are provided with a connector for connecting a stiffening member to the peripheral edge, said stiffening member being provided to link said parts under tension. An air cargo container comprising a skeleton structure of interconnected frame members to which are arranged face panels forming at least one wall between the frame members. At least one of the walls comprises an opening providing access to the interior of the container, whereby ...more ...less
13
US9150353B2
Publication/Patent Number: US9150353B2
Publication date: 2015-10-06
Application number: 13/951,234
Filing date: 2013-07-25
Inventor: Jackson, Randy W.  
Abstract: In an embodiment, a wind-resistant container system includes a container including a receiving space and an opening that provides access to the receiving space. The system also includes a lid connected to the container that is movable between an open position, and a closed portion, wherein the lid substantially covers the opening. One or more closure elements are configured to selectively secure the lid in the closed portion such that the receiving space is protected from wind. The system further includes an anchoring system operably connected to the container and configured to anchor the container on a wall structure without forming a permanent hole in the wall structure. The anchoring system includes a front portion positionable on a first surface of the wall structure and a back portion positionable on a second surface of the wall structure. In an embodiment, a wind-resistant container system includes a container including a receiving space and an opening that provides access to the receiving space. The system also includes a lid connected to the container that is movable between an open position, and a closed ...more ...less